Internal Medicine Department, State Medical University of Zaporozhye, 26, Mayakovsky av., Zaporozhye, UA-69035, Ukraine.
Internal Medicine Department, Medical Academy of Post-Graduate Education, Ministry of Health of Ukraine, Zaporozhye, 69096, Ukraine.
Future Cardiol. 2021 May;17(3):497-506. doi: 10.2217/fca-2020-0178. Epub 2021 Feb 22.
Current clinical guidelines for heart failure (HF) contain a brand new therapeutic strategy for HF with reduced ejection fraction (HFrEF), which is based on neurohumoral modulation through the use of angiotensin receptor neprilysin inhibitors. There is a large body of evidence for the fact that sodium-glucose co-transporter 2 inhibitors may significantly improve all-cause mortality, cardiovascular mortality and hospitalization for HF in patients with HFrEF who received renin-angiotensin system blockers including angiotensin receptor neprilysin inhibitors, β-blockers and mineralocorticoid receptor antagonists. The review discusses that sodium-glucose co-transporter 2 inhibitors have a wide spectrum of favorable molecular effects and contribute to tissue protection, improving survival in HFrEF patients.
目前心力衰竭（HF）的临床指南包含了一种针对射血分数降低的心力衰竭（HFrEF）的全新治疗策略，该策略基于通过使用血管紧张素受体脑啡肽酶抑制剂来调节神经体液。有大量证据表明，钠-葡萄糖共转运蛋白 2 抑制剂可显著降低接受肾素-血管紧张素系统抑制剂（包括血管紧张素受体脑啡肽酶抑制剂、β受体阻滞剂和盐皮质激素受体拮抗剂）治疗的 HFrEF 患者的全因死亡率、心血管死亡率和心力衰竭住院率。该综述讨论了钠-葡萄糖共转运蛋白 2 抑制剂具有广泛的有利分子作用，并有助于组织保护，改善 HFrEF 患者的生存。
